Comparing open and robot-assisted removal of groin lymph nodes for penile cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter surgical comparison looks at outcomes after traditional open inguinal lymphadenectomy versus a robot-assisted minimally invasive approach in men requiring groin lymph node removal for penile squamous cell carcinoma. Eligible patients who have an indication for prophylactic or therapeutic inguinal lymphadenectomy will undergo one of the two surgical techniques and be followed for postoperative complications, wound morbidity, time to recovery, and timing of any adjuvant therapy. The trial will also record nodal staging, recurrence patterns, and other oncologic outcomes. The overall goal is to see if a robot-assisted approach can reduce the high complication rates and long convalescence associated with open surgery.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 1\. Patient has provided written informed consent.
* 2\. Male patient ≥ 18 years at time of signing the informed consent form.
* 3\. Patient has histologically proven penile squamous cell carcinoma.
* 4\. Patient has indication for prophylactic (intermediate or high-risk primary tumor and cN0) or therapeutic (cN1/2) inguinal lymphadenectomy, i.e.:

  * pT1a, G2, cN0 OR
  * pT1b- pT3, any G, cN0 OR
  * pTa-pT3, any G, cN1-2
* 5\. Patients has adequate hepatic, renal and bone marrow function:

  * Hemoglobin ≥ 8.0 g/dL
  * Absolute neutrophil count ≥ 1.5 x 109 /L
  * Platelets ≥ 100 x 109 /L
  * International normalized ratio (INR) / activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN unless participant is receiving anticoagulant therapy as long as PTT is within therapeutic range of intended use of anticoagulants. Anticoagulation is accepted according to the surgeon's practice.
* 6\. Patient is willing and able to comply with the protocol for the duration of the study, including hospital visits for treatment and scheduled follow-up visits and examinations.
* 7\. Performance status of the patient is judged by the treating physician as appropriate to undergo surgery.

Exclusion Criteria:

* 1\. Patients has inguinal bulky disease ≥ 4 cm (determined by ultrasound or cross-sectional imaging).
* 2\. Patient has distant metastases.
* 3\. Patient receives or is scheduled for neoadjuvant chemotherapy for PeCa.
* 4\. Patient received previous major inguinal surgery (transabdominal laparoscopic inguinal hernia repair is permitted), sentinel or other lymph node resection or radiotherapy in the groin or pelvic area.
* 5\. Patient participates in competing trials affecting the effects of the surgery or outcome measures.
* 6\. Patient has addictive or other medical conditions that do not allow the subject to appreciate the nature and scope of the clinical trial and its potential consequences.
* 7\. Patient has any co-existing medical condition that in the investigator's judgement will substantially increase the risk associated with the patient's participation in the study.
* 8\. Patient has been incarcerated or involuntarily institutionalized by court order or by the authorities.
* 9\. Patient is unable to consent because he does not understand the nature, significance and implications of the clinical trial and therefore cannot form a rational intention in the light of the facts.

Where it's running

• Charité- Universitätsmedizin Berlin
  Berlin, Germany Recruiting
• University Hospital Carl Gustav Carus
  Dresden, Germany Recruiting
• Universitätsklinikum Erlangen
  Erlangen, Germany Recruiting
• University Medical Center of Johannes Gutenberg-University
  Mainz, Germany Recruiting
• Medical Faculty Mannheim
  Mannheim, Germany Recruiting
• University Medicine Rostock
  Rostock, Germany Recruiting

Study contacts

• Principal investigator: Igor Tsaur, Prof. Dr. — University Hospital Tuebingen, Medical Faculty, Eberhard-Karls-University
• Study coordinator: Annemarie Uhlig, Prof. Dr. med.
• Email: vertrag.uro-studien@med.uni-tuebingen.de
• Phone: +4970712987235

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• EGFR-targeted therapy plus PD-1 blocker before surgery for advanced penile cancer

  This phase II trial tests whether Becotatug vedotin plus Pucotenlimab given before surgery can shrink tumors in men with advanced penile cancer and help preserve the penis when possible.

  Recruiting Phase 2 West China Hospital · Chengdu, Sichuan · NCT07518979

• Beocotatug Vedotin plus Pucotenlimab for EGFR-positive advanced penile cancer

  This trial tests whether a targeted antibody-drug conjugate plus a PD-1 inhibitor can help people with EGFR-positive advanced penile cancer who have limited or no chemotherapy options.

  Recruiting Phase 2 Fudan University · Shanghai · NCT07497919

• QL1706 with lenvatinib for previously treated penile cancer

  This trial tests whether combining QL1706 with lenvatinib can help control advanced or metastatic penile squamous cell carcinoma in people whose disease progressed after prior treatments.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07384416

• MRG003 plus HX008 for EGFR-positive advanced or metastatic penile squamous cell carcinoma

  This trial tests whether combining the EGFR-targeted antibody-drug conjugate MRG003 with the PD-1 inhibitor HX008 works as a first-line treatment for men with EGFR-positive advanced or metastatic penile cancer.

  Recruiting Phase 1 West China Hospital · Chengdu, Sichuan · NCT07054307

• Treatment of rare advanced tumors with a combination of drugs

  This study is testing a new combination of drugs to see if it can help people with rare advanced tumors live longer and feel better.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT06684327

• Using Ivocizumab to treat various advanced rare tumors

  This study is testing if a new treatment called Ivocizumab can help people with different types of advanced rare tumors feel better and live longer.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT06683846

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.